GeoVax Labs (GOVX) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 08, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'GeoVax Labs, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	25,468,037
Amendment Flag	'false	'
Entity Central Index Key	'0000832489	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$1,371,802	$2,513,861
Grant funds receivable	'	140,909
Prepaid expenses and other current assets	29,161	43,569
Total current assets	1,400,963	2,698,339
Property and equipment, net	103,647	120,227
Other assets	16,010	21,010
Total assets	1,520,620	2,839,576
Current liabilities:	'	'
Accounts payable	115,376	155,943
Accrued expenses	10,918	96,406
Amounts payable to Emory University (a related party)	111,200	60,000
Total current liabilities	237,494	312,349
Commitments (Note 5)	'	'
Stockholders’ equity:	'	'
Issued and outstanding shares – 25,168,037 and 23,765,180 at June 30, 2014 and December 31, 2013, respectively	25,168	23,765
Additional paid-in capital	28,669,528	28,239,392
Deficit accumulated during the development stage	-28,347,540	-27,052,085
Total stockholders’ equity	1,283,126	2,527,227
Total liabilities and stockholders’ equity	1,520,620	2,839,576
Series A Convertible Preferred Stock [Member]	'	'
Stockholders’ equity:	'	'
Preferred stock	'	60,586
Series B Convertible Preferred Stock [Member]	'	'
Stockholders’ equity:	'	'
Preferred stock	$935,970	$1,255,569

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, par or stated value (in Dollars per share)	$0.01	$0.01
Prеfеrrеd stock, sharеs authorizеd	10,000,000	10,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, authorized shares	75,000,000	75,000,000
Common stock, issued shares	25,168,037	23,765,180
Common stock, outstanding shares	25,168,037	23,765,180
Series A Convertible Preferred Stock [Member]	'	'
Preferred stock, par or stated value (in Dollars per share)	$1,000	$1,000
Prеfеrrеd stock, sharеs issuеd	0	71
Prеfеrrеd stock, sharеs outstanding	0	71
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, par or stated value (in Dollars per share)	$1,000	$1,000
Prеfеrrеd stock, sharеs issuеd	1,230	1,650
Prеfеrrеd stock, sharеs outstanding	1,230	1,650

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Grant revenue	$180,441	$441,561	$337,781	$1,238,601
Operating expenses:	'	'	'	'
Research and development	516,202	553,199	919,062	1,435,187
General and administrative	344,862	415,784	716,664	1,028,727
Total operating expenses	861,064	968,983	1,635,726	2,463,914
Loss from operations	-680,623	-527,422	-1,297,945	-1,225,313
Other income:	'	'	'	'
Interest income	1,086	1,138	2,490	2,232
Total other income	1,086	1,138	2,490	2,232
Net loss	($679,537)	($526,284)	($1,295,455)	($1,223,081)
Basic and diluted:	'	'	'	'
Loss per common share (in Dollars per share)	($0.03)	($0.02)	($0.05)	($0.06)
Weighted averages shares outstanding (in Shares)	25,075,729	21,089,687	24,921,376	20,630,515

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($1,295,455)	($1,223,081)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	32,744	35,101
Stock-based compensation expense	51,354	321,420
Changes in assets and liabilities:	'	'
Grant funds receivable	140,909	230,498
Prepaid expenses and other current assets	14,408	13,618
Accounts payable and accrued expenses	-74,855	-175,422
Total adjustments	164,560	425,215
Net cash used in operating activities	-1,130,895	-797,866
Cash flows from investing activities:	'	'
Purchase of property and equipment	-11,164	'
Net cash used in investing activities	-11,164	'
Cash flows from financing activities:	'	'
Net proceeds from sale of common stock	'	1,643,334
Net cash provided by financing activities	'	1,643,334
Net increase (decrease) in cash and cash equivalents	-1,142,059	845,468
Cash and cash equivalents at beginning of period	2,513,861	1,035,925
Cash and cash equivalents at end of period	$1,371,802	$1,881,393

Note_1_Description_of_Company_

Note 1 - Description of Company and Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1.     Description of Company and Basis of Presentation
	GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a biotechnology company whose planned principal operations are the design, testing, manufacturing and sale (either directly or through licensees) of vaccines to treat human diseases. Our current focus is on developing vaccines that prevent and fight Human Immunodeficiency Virus (“HIV”) infections, and we are conducting research and development activities to commercialize certain patented technology licensed to us. HIV infections result in Acquired Immunodeficiency Syndrome (“AIDS”). We have exclusively licensed from Emory University (“Emory”) vaccine technology which was developed in collaboration with the National Institutes of Health (“NIH”) and the Centers for Disease Control and Prevention (“CDC”). GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).
	Our most advanced vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and western Europe. Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as an immunotherapy for individuals who are already infected with HIV. These vaccines are currently being evaluated in humans -- both in those infected with HIV and those who are not. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners.
	Our activities are subject to significant risks and uncertainties. We have neither received regulatory approval for any of our vaccine candidates, nor do we have any commercialization capabilities; therefore, it is possible that we may never successfully derive significant product revenues from any of our existing or future development programs or product candidates.
	We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We believe that our existing cash resources, combined with the proceeds from the NIH grants discussed in Note 8, will be sufficient to fund our planned operations into the first quarter of 2015. We will require additional funds to continue our planned operations beyond that date, and we are currently seeking sources of non-dilutive capital through government grant programs and clinical trial support. We also intend to conduct additional offerings of our equity securities. However, additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we may be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.
	The accompanying condensed consolidated financial statements at June 30, 2014 and for the three month and six month periods ended June 30, 2014 and 2013 are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.
	We disclosed in Note 2 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 those accounting policies that we consider significant in determining our results of operations and financial position. There have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10-K.

Note_2_Recent_Accounting_Prono

Note 2 - Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block [Abstract]	'
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	'
	2.     Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for the Company beginning in 2017 and allows for either full retrospective adoption or modified retrospective adoption. The Company is currently evaluating the impact of the adoption of Topic 606 on its financial statements.
	In June 2014, the FASB issued Accounting Standards Update 2014-10, Development Stage Entities (Topic 915) ("ASU 2014-10"). The amendments in ASU 2014-10 remove the definition of a development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows, and shareholder’s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. We have evaluated this accounting standard and determined it to have a material impact on our financial statements. We adopted ASU-2014-10 effective June 30, 2014 and the effects of the adoption are reflected in our financial statements and footnotes contained herein.
	There have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2014, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which we expect to have a material impact on our financial statements.

Note_3_Basic_and_Diluted_Loss_

Note 3 - Basic and Diluted Loss Per Common Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	3.     Basic and Diluted Loss Per Common Share
	Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 12.8 million and 10.4 million shares at June 30, 2014 and 2013, respectively.

Note_4_Balance_Sheet_Component

Note 4 - Balance Sheet Components	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Supplemental Balance Sheet Disclosures [Text Block]	'
	4.     Balance Sheet Components
	The tables below provide a breakdown of certain line items on the accompanying condensed consolidated balance sheets.
		June 30,			December 31,
		2014			2013
	Property and equipment:
	Laboratory equipment	$	485,767		$	474,603
	Leasehold improvements		115,605			115,605
	Other furniture, fixtures & equipment		28,685			28,685
	Total property and equipment		630,057			618,893
	Accumulated depreciation and amortization		(526,410	)		(498,666	)
	Property and equipment, net	$	103,647		$	120,227

Note_5_Commitments

Note 5 - Commitments	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Commitments Disclosure [Text Block]	'
	5.     Commitments
	Lease Agreement
	We lease approximately 8,400 square feet of office and laboratory space located in Smyrna, Georgia (metropolitan Atlanta). As of June 30, 2014, our future minimum lease payments pursuant to the 62 month operating lease total $64,780 for the remainder of 2014.
	Other Commitments
	In the normal course of business, we may enter into various firm purchase commitments related to production and testing of our vaccines, conduct of our clinical trials, and other research-related activities. As of June 30, 2014, we had approximately $25,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in 2014.

Note_6_Stockholders_Equity

Note 6 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	6.     Stockholders’ Equity
	Preferred Stock Transactions
	During the six months ended June 30, 2014, we issued an aggregate of 202,857 and 1,200,000 shares of our common stock related to conversions of our Series A and Series B Convertible Preferred Stock, respectively. As of June 30, 2014, there are no shares of our Series A Convertible Preferred Stock outstanding, and 1,230 shares of our Series B Convertible Preferred Stock outstanding, convertible into 3,514,286 shares of our common stock.
	Common Stock Transactions
	Other than common stock issued pursuant to the conversion of our Series A and Series B Convertible Preferred Stock described above, we issued no shares of our common stock during the six months ended June 30, 2014.
	Stock Options
	We maintain a stock option plan that provides the Board of Directors broad discretion in creating equity incentives for employees, officers, directors and consultants. The following table presents a summary of stock option transactions during the six months ended June 30, 2014:
		Number of Shares			Weighted Average
					Exercise Price
	Outstanding at December 31, 2013		1,197,044		$	3.79
	Granted		7,500			0.29
	Exercised		--			--
	Forfeited or expired		(223,245	)		1.91
	Outstanding at June 30, 2014		981,299		$	4.19
	Exercisable at June 30, 2014		624,793		$	6.23
	Stock Purchase Warrants
	We have previously issued stock purchase warrants in connection with financing transactions and also in exchange for services from consultants and others. As of June 30, 2014, there are 8,284,826 stock purchase warrants outstanding, with a weighted average exercise price of $2.07.
	Stock-Based Compensation Expense
	During the three month and six month periods ended June 30, 2014, we recorded share-based compensation expense related to stock options of $25,047 and $51,354, as compared to $35,978 and $83,252 for the three month and six month periods ended June 30, 2013, respectively. Share-based compensation expense is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of June 30, 2014, there was $131,512 of unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted average period of 1.8 years.
	During the three and six month periods ended June 30, 2014 and 2013, we recorded no expense related to the issuance of stock purchase warrants in exchange for services; and as of June 30, 2014, there was no unrecognized compensation expense related to any compensatory warrant arrangements. During the three month and six month periods ended June 30, 2013, we recorded $19,617 and $238,168 of general and administrative expense associated with certain modifications to then-outstanding stock purchase warrants.
	Common Stock Reserved
	A summary of our common stock reserved for future issuance is as follows as of June 30, 2014:
	Series B Convertible Preferred Stock		3,514,286
	Common Stock Purchase Warrants		8,284,826
	Equity Incentive Plans		1,197,529
	Total		12,996,641

Note_7_Income_Taxes

Note 7 - Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	7.     Income Taxes
	Because of our historically significant net operating losses, we have not paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits may be subject to substantial annual limitations due to ownership change provisions of Section 382 of the Internal Revenue Code. The annual limitation may result in the expiration of net operating losses and credits before utilization.

Note_8_Government_Grants

Note 8 - Government Grants	6 Months Ended
	Jun. 30, 2014
Government Grants [Abstract]	'
Government Grants [Text Block]	'
	8.     Government Grants
	In September 2007, the NIH awarded us an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant to support our HIV/AIDS vaccine program. We are utilizing this funding to further our HIV/AIDS vaccine development, optimization and production. The aggregate award (including subsequent amendments) totaled approximately $20.4 million and, as of June 30, 2014, there is $484,499 of unrecognized grant funds remaining and available for use through the end of the grant period (August 31, 2014).
	In July 2013, the NIH awarded us a Small Business Innovative Research (SBIR) grant entitled “Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine.” The initial grant award of approximately $277,000 is for the first year of a two year project period beginning August 1, 2013 and has been fully utilized as of June 30, 2014. In July 2014, the NIH awarded us a grant of approximately $290,000 for the second year of the project period.
	We record revenue associated with these grants as the related costs and expenses are incurred and such revenue is reported as a separate line item in our statements of operations. During the three month and six month periods ended June 30, 2014, we recorded $180,441 and $337,781 of revenue associated with these grants, as compared to $441,561 and $1,238,601 for the three month and six month periods ended June 30, 2013, respectively

Note_9_Related_Party_Transacti

Note 9 - Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	9.     Related Party Transactions
	We are obligated to reimburse Emory University (a significant stockholder of the Company) for certain prior and ongoing costs in connection with the filing, prosecution and maintenance of patent applications subject to our technology license agreement from Emory. During the six month period ended June 30, 2014, we recorded $115,393 of general and administrative expense associated with these patent cost reimbursements to Emory.

Note_10_Subsequent_Events

Note 10 - Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	10.     Subsequent Events
	In July 2014, we issued 250,000 shares of our common stock for certain consulting services from a third party and recorded stock-based compensation expense of $50,000 related to the issuance.
	As discussed in Note 8, in July 2014, the NIH awarded us a $290,000 SBIR grant entitled “Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine.” This grant award is for the second year of a two year project period beginning August 1, 2013.
	In August 2014, we issued 50,000 shares of our common stock related to conversions of our Series B Convertible Preferred Stock.

Note_4_Balance_Sheet_Component1

Note 4 - Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Scedule of Property, Equipment and Other Assets [Table Text Block]	'
		June 30,			December 31,
		2014			2013
	Property and equipment:
	Laboratory equipment	$	485,767		$	474,603
	Leasehold improvements		115,605			115,605
	Other furniture, fixtures & equipment		28,685			28,685
	Total property and equipment		630,057			618,893
	Accumulated depreciation and amortization		(526,410	)		(498,666	)
	Property and equipment, net	$	103,647		$	120,227

Note_6_Stockholders_Equity_Tab

Note 6 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
		Number of Shares			Weighted Average
					Exercise Price
	Outstanding at December 31, 2013		1,197,044		$	3.79
	Granted		7,500			0.29
	Exercised		--			--
	Forfeited or expired		(223,245	)		1.91
	Outstanding at June 30, 2014		981,299		$	4.19
	Exercisable at June 30, 2014		624,793		$	6.23
Schedule of Stock by Class [Table Text Block]	'
	Series B Convertible Preferred Stock		3,514,286
	Common Stock Purchase Warrants		8,284,826
	Equity Incentive Plans		1,197,529
	Total		12,996,641

Note_3_Basic_and_Diluted_Loss_1

Note 3 - Basic and Diluted Loss Per Common Share (Details)	3 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12.8	10.4

Note_4_Balance_Sheet_Component2

Note 4 - Balance Sheet Components (Details) - Property and Equipment, and Other Assets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Property and equipment:	'	'
Property and equipment, gross	$630,057	$618,893
Accumulated depreciation and amortization	-526,410	-498,666
Property and equipment, net	103,647	120,227
Laboratory Equipment [Member]	'	'
Property and equipment:	'	'
Property and equipment, gross	485,767	474,603
Leasehold Improvements [Member]	'	'
Property and equipment:	'	'
Property and equipment, gross	115,605	115,605
Other Furniture, Fixtures and Equipment [Member]	'	'
Property and equipment:	'	'
Property and equipment, gross	$28,685	$28,685

Note_5_Commitments_Details

Note 5 - Commitments (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
	sqft
Disclosure Text Block Supplement [Abstract]	'
Area of Real Estate Property (in Square Feet)	8,400
Lessee Leasing Arrangements, Operating Leases, Term of Contract	'62 months
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	$64,780
Unrecorded Unconditional Purchase Obligation	$25,000

Note_6_Stockholders_Equity_Det

Note 6 - Stockholders' Equity (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

'

'

'

202,857

'

1,200,000

'

0

'

Preferred Stock, Shares Outstanding (in Shares)

'

'

'

'

'

'

0

71

1,230

1,650

'

'

Convertible Preferred Stock, Total Conversion Shares (in Shares)

'

'

'

'

'

'

'

'

3,514,286

'

'

'

Class of Warrant or Right, Outstanding (in Shares)

8,284,826

'

8,284,826

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$2.07

'

$2.07

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

$25,047

$35,978

$51,354

$83,252

$19,617

$238,168

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

131,512

'

131,512

'

'

'

'

'

'

'

'

0

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'1 year 292 days

'

'

'

'

'

'

'

'

'

Issuance of Stock and Warrants for Services or Claims

$0

$0

$0

$0

'

'

'

'

'

'

'

'

Note_6_Stockholders_Equity_Det1

Note 6 - Stockholders' Equity (Details) - Activity of Stock Option Plan (USD $)	6 Months Ended
	Jun. 30, 2014
Activity of Stock Option Plan [Abstract]	'
Outstanding at December 31, 2013	1,197,044
Outstanding at December 31, 2013	$3.79
Granted	7,500
Granted	$0.29
Forfeited or expired	-223,245
Forfeited or expired	$1.91
Outstanding at June 30, 2014	981,299
Outstanding at June 30, 2014	$4.19
Exercisable at June 30, 2014	624,793
Exercisable at June 30, 2014	$6.23

Note_6_Stockholders_Equity_Det2

Note 6 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance	Jun. 30, 2014
Class of Stock [Line Items]	'
Common Stock Reserved for Future Issuance	12,996,641
Series B Convertible Preferred Stock [Member]	'
Class of Stock [Line Items]	'
Common Stock Reserved for Future Issuance	3,514,286
Warrant [Member]	'
Class of Stock [Line Items]	'
Common Stock Reserved for Future Issuance	8,284,826
Equity Incentive Plans [Member]	'
Class of Stock [Line Items]	'
Common Stock Reserved for Future Issuance	1,197,529

Note_8_Government_Grants_Detai

Note 8 - Government Grants (Details) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

23 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jul. 31, 2014

Aug. 31, 2012

Jun. 30, 2014

Jul. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Subsequent Event [Member]

First NIH Grant [Member]

First NIH Grant [Member]

SBIR Grant [Member]

NIH Grants [Member]

NIH Grants [Member]

NIH Grants [Member]

NIH Grants [Member]

SBIR Grant [Member]

Note 8 - Government Grants (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Grant Award

'

'

'

'

$290,000

$20,400,000

'

$277,000

'

'

'

'

Unused Grant Funds

'

'

'

'

'

'

484,499

'

'

'

'

'

Revenue from Grants

$180,441

$441,561

$337,781

$1,238,601

'

'

'

'

$180,441

$441,561

$337,781

$1,238,601

Note_9_Related_Party_Transacti1

Note 9 - Related Party Transactions (Details) (General and Administrative Expense [Member], Emory [Member], USD $)	6 Months Ended
	Jun. 30, 2014
General and Administrative Expense [Member] | Emory [Member]	'
Note 9 - Related Party Transactions (Details) [Line Items]	'
Related Party Transaction, Expenses from Transactions with Related Party	$115,393

Note_10_Subsequent_Events_Deta

Note 10 - Subsequent Events (Details) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	6 Months Ended	1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Aug. 31, 2014	Jun. 30, 2014	Jul. 31, 2014	Jul. 31, 2014	Jul. 31, 2013
					Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Subsequent Event [Member]	Subsequent Event [Member]	SBIR Grant [Member]
					Subsequent Event [Member]		SBIR Grant [Member]
Note 10 - Subsequent Events (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	'	'	'	'	'	'	250,000	'
Issuance of Stock and Warrants for Services or Claims	$0	$0	$0	$0	'	'	'	$50,000	'
Grant Award	'	'	'	'	'	'	$290,000	'	$277,000
Stock Issued During Period, Shares, New Issues	'	'	'	'	50,000	1,200,000	'	'	'